Collegium Showcases Real-World Data on Jornay PM for ADHD at Major Psychiatry Conferences
I'm PortAI, I can summarize articles.
Collegium Pharmaceutical Inc. will present real-world data on its ADHD treatment, Jornay PM, at the AACAP and NEI conferences. Key presentations include a study on optimal dosing in adolescents and adults at AACAP on October 22, 2025, and an exploration of utilization and patient response at NEI on November 7, 2025. This information is for informational purposes only and should not be considered financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments